Grant Thornton tasked to probe allegations of Fortis fund diversion

Grant Thornton will investigate allegations of fund diversion from Fortis Healthcare by former promoters Malvinder and Shivinder Singh,has learnt.

The audit and advisory firm is expected to be formally appointed by law firm Luthra & Luthra, which was enlisted by Fortis in March to conduct an independent probe into the alleged siphoning of cash from the healthcare group.

Grant Thornton will analyse transactions involving investments and advances by a Fortis subsidiary to entities allegedly belonging to the promoter group, said people aware of the development. The investigation will focus on the antecedents of the parties that received the funds, establish if they were related parties when the money was transferred to them and identify the amount returned.

The remit of the investigation will include Fortis Healthcare’s expense accounts to verify if the beneficiaries had other business relationships with the company. Grant Thornton has been asked to find out if processes were violated when the disbursements were sanctioned, the people added. Grant Thornton’s report on the investigation will be made available to Luthra & Luthra alone, they said.

Luthra & Luthra and Grant Thornton declined to comment on the matter. Queries sent to Fortis Healthcare were unanswered by press time on Thursday.

Grant Thornton partners Vidya Rajarao and Samir Paranjpe oversee forensic investigations at the firm.

Fortis Healthcare, which is the target of an acquisition by TPG-backed Manipal Health Enterprises, has been under scrutiny following a Bloomberg report in February that stated the Singh brothers had withdrawn about ₹500 crore from the hospital group without board approval.

The report said Fortis auditor Deloitte Haskins & Sells had refused to sign off on group’s results for Q2 of FY18 until the funds were accounted for.

  • Related Posts

    Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

    AiMeD welcomes the move long overdue to boost India’s Regulatory Framework New Delhi: 21 Drug Inspectors have been promoted to Assistant Drugs Controllers (India) under CDSCO. It was long unmet…

    Yashoda Medicity lifts Benchmark in Critical Care to New High

    With the introduction of North India’s first Advanced VitalGo Total Lift Bed Technology Ghaziabad/ New Delhi: In an ideal hospital, critical care is most paramount and it is also the…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Delhi Police Bust ₹9-Crore Interstate Cancer Drug Diversion Network: 17 Arrested; 588 Anti-Cancer Vials, ₹50 Lakh Cash Seized

    Delhi Police Bust ₹9-Crore Interstate Cancer Drug Diversion Network: 17 Arrested; 588 Anti-Cancer Vials, ₹50 Lakh Cash Seized

    ‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy

    ‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    US appeals court sides with Sun Pharma in Lipitor antitrust case